Plain-English translation of NCT00801333 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are asking people with ALS to donate a small skin sample. Scientists will then reprogram these cells in the laboratory into a special type called induced pluripotent stem cells (iPSCs), which can grow into many different cell types. This allows researchers to study ALS disease mechanisms in human cells and test potential new therapies.
Currently, there are limited ways to study how ALS develops in human cells. By creating patient-derived stem cells, researchers hope to better understand what causes the disease and identify new treatment approaches that could help people with ALS.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be asked to provide a small skin sample, which researchers will use to create stem cells in the laboratory. All of your personal information will be kept confidential and removed from the samples. The study is primarily laboratory-based research; there are no ongoing treatments or multiple visits required from you as a participant.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Israel
Enrollment target
~25 participants
Started
November 2008
Primary completion
December 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Benjamin E. Reubinoff, M.D. PhD.
Chairman of Department of Obstetrics & Gynecology/IVF, Hadassah Ein Kerem
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.